A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808
| Status: | Completed |
|---|---|
| Conditions: | Alzheimer Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 55 - Any |
| Updated: | 7/16/2013 |
| Start Date: | July 2012 |
| End Date: | June 2013 |
| Contact: | Lydia M Su, Ph.D |
| Email: | msu@uci.edu |
| Phone: | 949-824-4925 |
A Phase 0, Open Label, Non-Randomized, Multi-Center, Exploratory and Safety Study of [F-18]T808
[F-18]T808 is being developed as a diagnostic radiopharmaceutical for PET imaging of the
human brain.
Siemens Molecular Imaging (SMI) is seeking to determine if [F-18]T808 might be useful as a
non-invasive assessment tool in the clinical evaluation of subjects with conditions
associated with tau protein aggregates, such as Alzheimer's disease. The information
collected under this exploratory study will not be used for diagnostic purposes, assessments
of the participant's response to therapy or for clinical management of the participants.
However, this exploratory study will provide baseline information on the safety,
biodistribution, and dosimetry of [F-18]T808. These data will aid in the design of future
studies of [F-18]T808 in patients with Alzheimer's disease. Overall, this study will provide
initial data that inform the development of [F-18]T808 as the first PET imaging agent for
human tau protein related pathology.
Low Probability for AD Participants (Group 1)
- Participant is of any race/gender/ethnicity who has reached his or her 55th birthday
at the time of informed consent.
- Participant provides written informed consent Participant is capable of complying
with study procedures
- Participant is capable of communicating with study personnel
- Participant understands and speaks English
- Participant has at least an 8th Grade education
- In the Investigator‟s opinion, participant has a low probability of being currently
positive for AD as determined by a Mini Mental State Examination (MMSE ≥ 28) defined
in APPENDIX VI of XXX protocol
- Participant has no significant hepatic or renal disease as defined by previous
medical history and lab results are within the following ranges: Total bilirubin
within 2x institutional upper limits of normal AST (SGOT) ≤ 2.5 x institutional upper
limits of normal ALT (SGPT) ≤ 2.5 x institutional upper limits of normal Creatinine ≤
2x institutional upper limits of normal BUN within 2x institutional upper limits of
normal
High Probability for AD Participants (Group 2)
- Participant is of any race/gender/ethnicity who has reached his or her 55th birthday
at the time of informed consent.
- Participant or participant‟s legally acceptable representative provides written
informed consent Participant is capable of complying with study procedures
- Participant is capable of communicating with study personnel
- Participant understands and speaks English
- Participant has at least an 8th Grade education In the Investigator‟s opinion,
*participant has a high probability of being currently positive for AD that is
determined by a Mini Mental State Examination (MMSE < 17) defined in APPENDIX VI of
XXX protocol
- Participant has no significant hepatic or renal disease as defined by previous
medical history, and lab results are within the following ranges: Total bilirubin
within 2x institutional upper limits of normal AST (SGOT) ≤ 2.5 x institutional upper
limits of normal ALT (SGPT) ≤ 2.5 x institutional upper limits of normal Creatinine ≤
2x institutional upper limits of normal BUN within 2x institutional upper limits of
normal
We found this trial at
1
site
University of California, Irvine Since 1965, the University of California, Irvine has combined the strengths...
Click here to add this to my saved trials
